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In their review of Pulmonary Resection in MetastaticColorectal Cancer, Pfannschmidt et al.1 consider carci-
noma embryonic antigen (CEA) as an adverse feature in
the prognosis of patients who have had pulmonary metas-
tasectomy for colorectal cancer, a consistent finding in
multivariable analyses of clinical case series.2,3 Kanemitsu
et al.3 published a predictive model on the basis of 313
patients operated on between 1989 and 1998. Their five
prognostic factors were primary histology, hilar or medi-
astinal lymph node involvement, number of metastases,
preoperative CEA level, and extrathoracic disease. How-
ever, CEA was not statistically significant in the most
recent Memorial Sloane Kettering report.4 They found that
in patients younger than 65 years, female sex, apparent
disease free interval (DFI) less than 1 year, and number of
metastases more than three to be predictive of recurrence
and went on to make an explicit recommendation: “med-
ical management alone should be considered standard for
patients who have both three or more pulmonary metasta-
ses and less than 1 year DFI.”
This contradiction prompts a consideration of the
role of CEA in the surveillance of patients with colorectal
cancer and in the selection of patients for surgery and of
the limitations of multivariate analysis as a basis for
clinical decision making.
First, to deal briefly with the statistical issue, the
failure to find a “p value” does not mean that CEA would
have had no bearing on outcome. If at the case selection
stage, there was a clinical policy (explicit or unstated) to
avoid operating on patients with high CEA, the range of
CEA data will have been curtailed at the input stage; there
is a point at which it cannot then emerge as a prognostic
factor. Other factors will then come to the fore.
It should also be remembered that there is a limit to
the number of factors that will emerge as significant and an
inevitable degree of variation in their apparent ranking.
The contradiction merits attention for surgeons who have
to make decisions about how to use CEA in their selection
of patients.5,6
In the systematic review by Fiorentino et al.,7 ap-
proximately a third of 51 included publications reported
the preoperative CEA in a way that could be used in the
analysis (Figure 1). Approximately half of these patients in
the operated series had an increased CEA in the earlier era
falling to approximately a third more recently. This illus-
trates the point alluded to above; there may have been a
conscious avoidance of metastasectomy for patients with
high CEA. The knowledge provided in earlier reports
might quite rightly have altered the practice, and hence the
case mix, for later reports. When CEA and survival data
were available, these showed (Figure 2) an evident and
consistent relationship: patients with increased CEA have
consistently worse survival. This suggests that the impor-
tance of a raised CEA as an adverse prognostic feature for
survival should not be forgotten just because it now fea-
tures less prominently in the input data set.
In the course of developing the PulMiCC trial,8,9 we
discovered that gastroenterologists and thoracic surgeons were at
cross purposes in the use of CEA in patients with recurrence of
colorectal cancer. While as thoracic surgeons we were interpret-
ing CEA as an adverse feature,3 some gastroenterologists were
using the CEA measurement as a surveillance tool: when CEA
became increased, this prompted a computed tomography scan
and possible referral to thoracic surgery if this revealed pulmo-
nary metastases. The practice may have stemmed in part from a
philosophy of care of colorectal cancer in which routine CEA
testing was used to prompt “second look” surgery to deal with
local recurrence10 and was at least temporally related to the
growth in hepatic metastasectomy for colorectal cancer.11 CEA
measurement was then shown to be not cost effective, because
although it picked up asymptomatic patients earlier, it made no
impact on survival.10,12,13
From the thoracic surgeons’ viewpoint, it would
seem reasonable to obtain a CEA measurement, and if it is
high, it should go in the balance pan adding weight against
metastasectomy. It is critical that the statistical findings are
used appropriately in surgical decision making. To rather
stretch the point, but to illustrate the point, here is a wry
Clinical Operational Research Unit, University College London, London,
UK.
Disclosure: The author declares no conflicts of interest.
Address for correspondence: Tom Treasure, MD, Clinical Operational Research
Unit, University College London, 4 Taviton Street, London WC1H 0BT,
United Kingdom. E-mail: tom.treasure@gmail.com
Copyright © 2010 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/10/0506-0179
Journal of Thoracic Oncology • Volume 5, Number 6, Supplement 2, June 2010 S179
observation on misunderstanding the statistical findings.
Although the distribution of hemoglobin measurements is
significantly different in populations of males and females,
measuring the hemoglobin is a poor way of discovering the
sex of a patient in front of you.
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FIGURE 1. In a systematic review
of 51 follow-up studies of pulmo-
nary metastasectomy for colorectal
cancer, 31 reported carcinoma em-
bryonic antigen (CEA).
FIGURE 2. Five-year survival ac-
cording to elevation of carcinoma
embryonic antigen (CEA).
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